Cann American Corp.

CNNA

US13764N2071

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 03:59:54 2024-05-10 pm EDT			5-day change	1st Jan Change
0.003 ^USD	+50.00%		+25.00%	-25.00%

2023	Cann American Corp. Reports Earnings Results for the Full Year Ended February 28, 2023	CI
2023	Cann American Corp. Auditor Raises 'Going Concern' Doubt	CI

CANN AMERICAN CORP. : Other Events (form 8-K)

March 24, 2023 at 09:55 am EDT

Item 8.01 - Other Events

On February 01, 2023, and effective March 15, 2023, the Company entered into an Agreement with Adam Scherr to act as a brand ambassador to the Company and Prodigy Stem Cell, LLC for a period of 12 months from the effective date. Mr. Scherr is a public figure, former professional strongman, and currently employed by World Wrestling Entertainment, Inc. (WWE). On March 15, 2023, the Company and Mr. Scherr further amended the Agreement where Mr. Scherr would act as a brand ambassador to the Company, and Prodigy Stem Cell, LLC through Country Strong Inc., an entity controlled by Mr. Scherr.

Latest news about Cann American Corp.

Cann American Corp. Reports Earnings Results for the Full Year Ended February 28, 2023	23-06-14	CI
Cann American Corp. Auditor Raises 'Going Concern' Doubt	23-06-13	CI
Cann American Corp. Appoints Michael G. Kramer as a Director	23-05-17	CI
Cann American Corp. completed the acquisition of acquire Liberty Health Plus.	23-05-09	CI
Cann American Corp. entered into a letter of intent to acquire Liberty Health Plus.	23-04-30	CI
Cann American Corp. Appoints Peter Caruso as Director	23-03-16	CI
Cann American Corp. acquired Prodigy Stem Cell, LLC.	23-03-15	CI
Cann American Corp. Announces Board and Executive Changes	23-02-06	CI
Cann American Corp. Announces CEO Changes	23-02-06	CI
Cann American Corp. Reinstates Jason Black as CEO	23-01-25	CI
Cann American Corp. Announces Executive Changes	23-01-25	CI
Cann American Corp. has entered into an additional binding letter of intent to acquire 75% equity in Valkyrie Systems Inc.	22-11-08	CI
Cann American Corp. Appoints Alexander Woods-Leo as CEO	22-11-02	CI
Cann American Corp. Announces Management Changes	22-11-02	CI
Cann American Corp. completed the acquisition of 80% stake in Mark2media Group LLC.	22-10-30	CI
Cann American Corp. entered into a binding letter of intent to acquire 80% stake in Mark2media Group LLC.	22-10-25	CI
Cann American Corp. Accepts the Resignation of Bradley Hanger as Director	22-10-24	CI
Cann American Corp. acquired Hourglass Enterprises LLC.	21-05-11	CI
Fly Beverage Corp. announced that it expects to receive funding from Cann American Corp.	20-05-03	CI
Canamed4Pets, Inc. will Change its Name to Cann American Corp	19-12-20	CI
Cann American Corp. entered into an agreement to acquire Cannequipt, LLC from Patrick King for $0.04 million.	19-10-20	CI
Bioflamex Corporation has Changed its Ticker to BFLXD from BFLX	14-09-04	CI
Bioflamex Corp. Introduces Emergency Escape System	13-09-10	CI
Terra Asset Management, Inc. cancelled the acquisition of Bioflamex Corporation in a reverse merger transaction.	12-10-16	CI
Bioflamex Corporation will Change its Ticker to BFLXE from BFLX	12-06-19	CI

Chart Cann American Corp.

Duration

Period

More charts

Company Profile

Cann American Corp. is a holding company. The Company is engaged in developing assets within the legal cannabis and hemp industries. The Company has two subsidiaries, Cannequipt, LLC and Hourglass Enterprises LLC. Cannequipt, LLC, intends to act as a research and development division. Hourglass Enterprises LLC, intends to focus on developing new assets in the state of Oklahoma. The Company primarily within the state of California.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CANN AMERICAN CORP.	-25.00%	2.21M
ELI LILLY AND COMPANY	+30.38%	684B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.36%	361B
MERCK & CO., INC.	+19.30%	329B
ABBVIE INC.	+3.73%	284B
ASTRAZENECA PLC	+16.70%	240B
NOVARTIS AG	+8.78%	208B
ROCHE HOLDING AG	-7.93%	200B
AMGEN INC.	+7.68%	166B

Other Pharmaceuticals